<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Aluminum toxicity in chronic kidney disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Aluminum toxicity in chronic kidney disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Aluminum toxicity in chronic kidney disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wajeh Y Qunibi, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Berns, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 17, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H202036068"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Aluminum toxicity is a systemic disorder observed in patients on hemodialysis and occasionally in patients who have severe chronic kidney disease (CKD; ie, glomerular filtration rate [GFR] &lt;30 mL/min/1.73 m<sup>2</sup>) but are not on dialysis. Aluminum toxicity primarily results from exposure to aluminum in dialysis fluid and from the ingestion of aluminum-containing phosphate binders among patients who cannot excrete it [<a href="#rid1">1</a>].</p><p>Aluminum toxicity is now uncommon because aluminum is removed from water used for dialysis and because nonaluminum-containing phosphate binders are widely available [<a href="#rid2">2</a>]. Aluminum toxicity is now thought to be limited to patients on hemodialysis in resource-limited countries where aluminum-based phosphate binders are occasionally used, patients in whom infrequent dialysate contamination occurs, and patients with unusual environmental exposures.</p><p>This topic reviews aluminum toxicity in patients with CKD, particularly in those on hemodialysis, in whom it is still occasionally observed. Other forms of bone disease commonly observed among patients with CKD are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1969.html" rel="external">"Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)"</a>.)</p><p>Techniques that are utilized for the removal of aluminum from dialysis water are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1896.html" rel="external">"Assuring water quality for hemodialysis"</a> and  <a class="medical medical_review" href="/d/html/1891.html" rel="external">"Contaminants in water used for hemodialysis"</a>.)</p><p>Nonaluminum phosphate binders are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1942.html" rel="external">"Management of hyperphosphatemia in adults with chronic kidney disease", section on 'Specific treatment'</a>.)</p><p class="headingAnchor" id="H23559462"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Aluminum toxicity used to be a fairly common problem among patients on hemodialysis worldwide. However, it is now uncommon in countries where the use of aluminum-based medications (eg, phosphate binders) has been abolished and strict dialysis water purification practices have been enforced [<a href="#rid2">2-4</a>]. Since 2003, 0.5 to 0.8 percent of patients on hemodialysis in the United States were found to have elevated serum aluminum levels [<a href="#rid2">2,5,6</a>]. Similarly, in one study of patients from Europe and the United States who underwent bone biopsies, aluminum staining was positive in only 0.6 percent of patients [<a href="#rid7">7</a>].</p><p>However, aluminum toxicity may still be a significant problem in certain other countries where limits on aluminum exposure among patients on dialysis are not strictly enforced [<a href="#rid8">8-10</a>]. As an example, in one study from Brazil, 38 percent of bone biopsies stained positive for aluminum [<a href="#rid10">10</a>]. </p><p>Occasionally, there are cases of aluminum toxicity clustered among patients dialyzed at a facility. These are usually either due to an increase in the aluminum content in the municipal water that supplies the dialysis facility or due to malfunction of the water purification and/or distribution system within a dialysis unit [<a href="#rid5">5,11,12</a>]. (See <a class="local">'Aluminum in dialysis fluid'</a> below and  <a class="medical medical_review" href="/d/html/1891.html" rel="external">"Contaminants in water used for hemodialysis", section on 'Aluminum'</a>.)</p><p>Aluminum toxicity among patients with nondialysis chronic kidney disease (CKD) is exceedingly rare. Most reports of aluminum toxicity in this group are from patients who were ingesting aluminum-containing medications concurrently with citrate [<a href="#rid13">13-15</a>]. Citrate increases the intestinal absorption of aluminum [<a href="#rid15">15</a>]. (See <a class="local">'Aluminum with citrate'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h1">SOURCES OF ALUMINUM</span><span class="headingEndMark"> — </span>The major sources of aluminum exposure among patients on hemodialysis include the dialysis fluid and aluminum-containing phosphate binders and antacids [<a href="#rid16">16-20</a>]. Other medications may also contain small amounts of aluminum that can accumulate in patients with end-stage kidney disease (ESKD).</p><p>Aluminum utensils used for cooking may also be a potential source of aluminum accumulation. In one study of patients with ESKD, cooking with aluminum utensils was associated with chronic aluminum toxicity; serum aluminum levels were approximately eight-fold higher than that of controls [<a href="#rid21">21</a>]. In another study of patients with chronic kidney disease, replacement of aluminum utensils led to improvement in serum aluminum levels [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H108667437"><span class="h2">Aluminum in dialysis fluid</span><span class="headingEndMark"> — </span>Municipal water supplies (which supply water to dialysis facilities) contain a relatively high concentration of aluminum. These concentrations are considered safe for the general population but are toxic for patients on hemodialysis. This is because patients on hemodialysis are exposed to very large volumes of dialysate water and have no means to excrete the aluminum that is in the fluid.</p><p>The toxicity of aluminum in dialysis water has been recognized since the 1970s [<a href="#rid23">23-25</a>]. This recognition led to the development of effective methods of water purification. In addition, after aluminum toxicity was recognized, stringent international and national guidelines were established that recommended the maximal allowable limit of aluminum in dialysate water. (See  <a class="medical medical_review" href="/d/html/1896.html" rel="external">"Assuring water quality for hemodialysis"</a> and  <a class="medical medical_review" href="/d/html/1891.html" rel="external">"Contaminants in water used for hemodialysis", section on 'Aluminum'</a>.)</p><p>The contribution of dialysis fluid to aluminum toxicity decreased markedly as a result of improved water purification [<a href="#rid1">1</a>]. The introduction of reverse osmosis for water purification has essentially eliminated the problem of water contamination with aluminum [<a href="#rid26">26</a>].</p><p>However, there are still occasional reports of high serum aluminum concentrations in patients on dialysis, despite water purification methods [<a href="#rid5">5,11,12</a>]. Such reports are all related to changes in the aluminum content of the municipal water supply or to defects in the water and dialysate purification and distribution systems within individual dialysis facilities [<a href="#rid5">5,11,12</a>]. As an example, in 2007, 10 patients with high serum aluminum concentrations were reported from a center in the United States [<a href="#rid5">5</a>]. The high aluminum concentrations resulted from contamination of dialysate acid concentrate by newly installed electric drum pumps [<a href="#rid5">5</a>]. In 2001, 27 patients dialyzed on the island of Curaçao, north of the Venezuelan coast, were exposed to toxic levels of aluminum resulting from the installation of a distribution pipe that supplied the dialysis facility with water; of these, 10 patients died from acute exposure [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/d/html/1891.html" rel="external">"Contaminants in water used for hemodialysis"</a> and <a class="local">'Acute encephalopathy'</a> below.)</p><p>In 2004 and 2005, several Canadian peritoneal dialysis centers noted increasing serum aluminum levels during yearly routine monitoring [<a href="#rid28">28</a>]. Investigation eventually documented high aluminum content in dialysates manufactured by Fresenius Canada. Serum aluminum was inversely correlated with kidney creatinine clearance. However, because the problem was detected rapidly, no clinical consequences were observed in the study cohort. The presence of residual kidney function was protective against aluminum accumulation.</p><p class="headingAnchor" id="H108667891"><span class="h2">Aluminum-containing phosphate binders and antacids</span><span class="headingEndMark"> — </span>Aluminum-containing phosphate binders and antacids are a source of aluminum toxicity in patients with CKD. However, their use was restricted after reports of aluminum-related neurologic and bone disease.</p><p>Both the Kidney Disease Outcomes Quality Initiative (KDOQI) and Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines advise against long-term use of aluminum-containing binders [<a href="#rid20">20,29</a>]. Aluminum-containing phosphate binders are now infrequently prescribed across the world but are still being used in Australia and Russia, as well as some other countries. A study from Russia showed that aluminum-containing phosphate binders were used in 17.6 percent of their patients on hemodialysis [<a href="#rid30">30</a>].</p><p>The use of aluminum-containing phosphate binders has declined because nonaluminum-containing phosphate binders are now widely available. However, some patients may still be given aluminum-containing phosphate binders for a brief period of time (one to two weeks). Such patients include those with refractory hyperphosphatemia (which may respond better to aluminum-containing phosphate binders) and those with side effects to nonaluminum-containing phosphate binders (such as hypercalcemia). However, given that the amount of aluminum intake required to cause toxicity is not known, there is no "safe" dose of aluminum-containing phosphate binder [<a href="#rid19">19</a>].</p><p>There are still occasional reports of high aluminum concentrations that are presumed to be due to phosphate binders. As an example, in one report, among 136 patients on hemodialysis (many who reported use of aluminum-containing phosphate binders), 16 percent had serum aluminum levels greater than 30 mcg/L, and, in three cases, aluminum levels were higher than 60 mcg/L [<a href="#rid31">31</a>]. In another study from Taiwan, 44 of 473 patients on hemodialysis who underwent annual serum aluminum testing were found to have predialysis serum aluminum levels of ≥20 mcg/L [<a href="#rid32">32</a>]. Many of these patients were receiving aluminum-based phosphate binders.</p><p>Aluminum levels greater than 20 mcg/L are considered abnormal. The elevated aluminum concentrations were believed to be primarily due to the use of aluminum-containing binders because the dialysis water was shown to be within the maximum allowable limit for aluminum.</p><p class="headingAnchor" id="H533965128"><span class="h2">Aluminum with citrate</span><span class="headingEndMark"> — </span>Citrate is a major factor in the toxicity of orally administrated aluminum [<a href="#rid15">15,33</a>]. Aluminum toxicity may occur in patients with CKD who are given aluminum-containing phosphate binders plus sodium citrate. Citrate markedly enhances intestinal aluminum absorption  (<a class="graphic graphic_figure graphicRef55777" href="/d/graphic/55777.html" rel="external">figure 1</a>) [<a href="#rid15">15,33,34</a>]. The mechanism by which this occurs is believed to be both by keeping aluminum soluble over the wider pH range (via the formation of aluminum citrate) and by chelating extracellular calcium leading to disruption of the integrity of intestinal epithelial cell tight junctions and opening the paracellular pathway for the absorption of soluble aluminum citrate [<a href="#rid33">33-35</a>].</p><p>The introduction of <a class="drug drug_general" data-topicid="96959" href="/d/drug information/96959.html" rel="external">ferric citrate</a> as a phosphate binder raised concern about enhanced aluminum absorption from drinking water, food, and drugs. However, one randomized control trial found no significant differences in serum aluminum levels between the ferric citrate-treated group and active control [<a href="#rid36">36</a>]. Among 185 participants in the ferric citrate group with available serum aluminum measurements, the median aluminum level was 6.0 (range, 5 to 24) mcg/L at baseline and 7.0 (5 to 23) mcg/L at the end of the 52-week active control period. These values were not significantly different from levels in the active control group [<a href="#rid36">36</a>]. Longer-term studies are needed to confirm these findings. Pending further data, regular monitoring for aluminum overload and toxicity has been suggested with long-term use of ferric citrate hydrate as a phosphate binder [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H108667938"><span class="h2">Other medications</span><span class="headingEndMark"> — </span>Other sources of aluminum include oral and injectable medications that are commonly administered to patients on dialysis [<a href="#rid38">38-42</a>]. Iron and calcium-containing medications have the highest aluminum levels, followed by <a class="drug drug_general" data-topicid="9183" href="/d/drug information/9183.html" rel="external">calcitriol</a> and vitamins B complex [<a href="#rid38">38</a>]. In one analysis, acetylsalicylic acid, calcitriol, <a class="drug drug_general" data-topicid="9285" href="/d/drug information/9285.html" rel="external">clonidine</a>, vitamins, iron sulfate, and <a class="drug drug_general" data-topicid="9185" href="/d/drug information/9185.html" rel="external">calcium carbonate</a> all contained between 85 and &gt;200 mcg/g [<a href="#rid38">38</a>]. Most preparations tested in this study had much lower aluminum concentrations. Injectable drugs have much greater contamination than oral formulations. Among the medications investigated, injectables such as iron, erythropoietin, and insulin were found to be the most significant source of aluminum for patients on hemodialysis [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H533968227"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>Routine monitoring of serum aluminum levels can identify excessive aluminum exposure in individual patients or detect accidental contamination of dialysate with aluminum [<a href="#rid20">20</a>].</p><p>However, given the low prevalence of aluminum toxicity among patients on hemodialysis patients, we do not routinely measure serum aluminum levels in all patients on hemodialysis. We believe that routine monitoring is not cost effective in most patients in the United States [<a href="#rid3">3,4,43</a>]. </p><p>This practice differs from the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines, which recommend serum aluminum testing at least annually in all patients on hemodialysis and every three months in those who receive aluminum-containing medications [<a href="#rid20">20</a>]. </p><p>We suggest monitoring the following patients:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients who receive hemodialysis in locations where water purification systems may be inadequate [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/d/html/1891.html" rel="external">"Contaminants in water used for hemodialysis", section on 'Aluminum'</a> and  <a class="medical medical_review" href="/d/html/1896.html" rel="external">"Assuring water quality for hemodialysis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients on dialysis and patients with nondialysis CKD who are receiving aluminum-based phosphate binders or who are on long-term treatment with <a class="drug drug_general" data-topicid="96959" href="/d/drug information/96959.html" rel="external">ferric citrate</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients (mostly those on hemodialysis) who are undergoing parathyroid surgery for CKD-related secondary hyperparathyroidism and who also have a history of aluminum exposure.</p><p></p><p>The optimal frequency and method of monitoring are not known. We monitor patients who are dialyzed in locations with inadequate water purification systems and those receiving aluminum-containing phosphate binders every four to six months [<a href="#rid19">19</a>]. We monitor for aluminum toxicity by measuring the unstimulated serum aluminum concentration (ie, the concentration in the absence of <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a>). Patients who are identified by monitoring to have serum aluminum concentration &gt;20 mcg/L should be evaluated further for aluminum toxicity. (See <a class="local">'Chronic toxicity'</a> below.)</p><p>However, one report found that many serum aluminum concentrations in the toxic range were not confirmed after retesting [<a href="#rid4">4</a>]. In such cases, patients should be retested with another specimen before investigating sources of exposure or undergoing treatment.</p><p>Patients who are undergoing parathyroid surgery for CKD-related secondary hyperparathyroidism and who also have a history of aluminum exposure should be evaluated prior to surgery with an unstimulated serum aluminum concentration [<a href="#rid44">44-46</a>]. If the unstimulated concentration is &lt;200 mcg/L, such patients should have further testing with a <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a> stimulation test (see <a class="local">'Chronic toxicity'</a> below). Evaluation of such patients is necessary because parathyroidectomy can worsen the clinical manifestations of aluminum toxicity among patients who have high aluminum concentrations. (See <a class="local">'Osteomalacia'</a> below and  <a class="medical medical_review" href="/d/html/1838.html" rel="external">"Refractory hyperparathyroidism and indications for parathyroidectomy in adult patients on dialysis"</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The clinical manifestations of aluminum toxicity may be chronic or acute, depending on the rate and amount of aluminum accumulation.</p><p class="headingAnchor" id="H533965660"><span class="h2">Chronic toxicity</span><span class="headingEndMark"> — </span>Manifestations of chronic aluminum toxicity result from exposure to low concentrations over a period of years. Chronic manifestations include bone and muscle pain, fracture, proximal muscle weakness, osteomalacia, iron-resistant microcytic anemia, hypercalcemia, and slowly progressive dementia [<a href="#rid16">16,17</a>].</p><p class="headingAnchor" id="H108668080"><span class="h3">Bone and muscle pain and muscle weakness</span><span class="headingEndMark"> — </span>Patients with aluminum toxicity complain of generalized bone and joint pain and proximal muscle weakness.</p><p>The joint symptoms may reflect aluminum deposition within the joint. High aluminum concentrations have been observed in synovial fluid of patients taking aluminum-containing phosphate binders [<a href="#rid47">47</a>]. However, joint aspiration is generally not done for diagnosis. (See <a class="local">'Diagnosis and evaluation'</a> below.)</p><p class="headingAnchor" id="H108668134"><span class="h3">Osteomalacia</span><span class="headingEndMark"> — </span>Aluminum toxicity used to be the most common cause of osteomalacia in patients with CKD but, as noted above, is now uncommon. The incidence of aluminum-induced osteomalacia is not known, since few bone biopsies are performed.</p><p>Osteomalacia is characterized by a very low rate of bone turnover, low number of bone-forming and bone-resorbing cells, a mineralization defect, and marked accumulation of unmineralized osteoid (bone matrix) [<a href="#rid16">16,17</a>]. (See  <a class="medical medical_review" href="/d/html/1969.html" rel="external">"Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)", section on 'Abnormalities in bone turnover, mineralization, volume linear growth, or strength'</a>.)</p><p>Aluminum overload causes defective mineralization, increased matrix synthesis by osteoblasts, inhibition of osteoblast differentiation, and the inhibition of osteoclast function [<a href="#rid48">48</a>].</p><p>Hyperparathyroidism, which is common among CKD patients, appears to protect against aluminum-induced osteomalacia, perhaps by increasing bone turnover [<a href="#rid17">17</a>]. This relationship becomes clinically important when therapeutic parathyroidectomy is being considered. Aluminum-induced osteomalacia must be excluded in such patients since lowering parathyroid hormone (PTH) levels by parathyroidectomy can lead to worsening of aluminum-induced osteomalacia [<a href="#rid17">17</a>] (see <a class="local">'Monitoring'</a> above and  <a class="medical medical_review" href="/d/html/1838.html" rel="external">"Refractory hyperparathyroidism and indications for parathyroidectomy in adult patients on dialysis"</a>). Lowering PTH levels medically by the administration of <a class="drug drug_general" data-topicid="9183" href="/d/drug information/9183.html" rel="external">calcitriol</a> also may accelerate aluminum bone disease, although this is less common [<a href="#rid49">49,50</a>].</p><p>The risk of aluminum-induced osteomalacia is greater in diabetic patients compared with nondiabetic patients [<a href="#rid51">51,52</a>]. The increased risk may be related to a lower than normal bone formation rate [<a href="#rid51">51,53</a>] and lower serum levels of PTH in patients with diabetes [<a href="#rid53">53-55</a>]. (See  <a class="medical medical_review" href="/d/html/1969.html" rel="external">"Overview of chronic kidney disease-mineral and bone disorder (CKD-MBD)", section on 'Abnormalities in bone turnover, mineralization, volume linear growth, or strength'</a>.)</p><p class="headingAnchor" id="H6"><span class="h3">Iron-resistant microcytic anemia</span><span class="headingEndMark"> — </span>Accumulation of aluminum in bone marrow causes a reversible microcytic anemia that is unaccompanied by evidence of iron deficiency. The anemia in such patients is resistant to iron supplementation [<a href="#rid20">20,56</a>]. The exact mechanism by which aluminum causes anemia is unclear but may involve displacing iron from transferrin [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H7"><span class="h3">Hypercalcemia</span><span class="headingEndMark"> — </span>Hypercalcemia may be observed among patients with aluminum-induced osteomalacia. Hypercalcemia is caused by aluminum deposition on the mineralization front, which blocks calcium uptake into bone. Aluminum toxicity should be suspected among CKD patients who have hypercalcemia without marked elevations in serum intact PTH (eg, &lt;500 pg/mL) and are not taking vitamin D or calcium supplements [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H8"><span class="h3">Dementia</span><span class="headingEndMark"> — </span>A slowly progressive dementia (formerly called dialysis dementia) results from prolonged aluminum toxicity. Aluminum-related dementia is characterized by dysarthria, myoclonus, mental changes, hallucinations, and seizures [<a href="#rid58">58</a>]. Symptoms are intermittent and may transiently worsen immediately following dialysis [<a href="#rid20">20</a>]. Increased aluminum has been described in the brain tissue of affected patients [<a href="#rid59">59</a>].</p><p>Epidemic forms of dialysis dementia have been reported in areas where the municipal water supply was heavily contaminated with aluminum [<a href="#rid1">1,20</a>]. Epidemic dialysis dementia has largely disappeared with the introduction of improved methods of water purification [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H533965688"><span class="h2">Acute toxicity</span><span class="headingEndMark"> — </span>Manifestations of acute aluminum toxicity result from exposure to very high concentrations of aluminum in the dialysate (ie, &gt;200 mcg/L). The major clinical manifestation is acute encephalopathy, which can be fatal [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H9"><span class="h3">Acute encephalopathy</span><span class="headingEndMark"> — </span>Acute aluminum-induced encephalopathy is characterized by altered consciousness, seizures, and coma [<a href="#rid20">20,27</a>]. The mortality of patients with acute aluminum-induced encephalopathy is high [<a href="#rid20">20,27</a>]. Aluminum-induced acute encephalopathy may occur in the following patients:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients on hemodialysis who are exposed to very high levels of aluminum in the dialysate (ie, &gt;200 mcg/L; the maximum allowable limit is 10 mcg/L). In this setting, most patients in the same dialysis center become ill simultaneously.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with nondialysis CKD with estimated glomerular filtration rate (GFR) &lt;30 mL/min/1.73 m<sup>2</sup> who are given aluminum-containing phosphate binders plus sodium citrate (ie, Bicitra or Shohl’s solution). Citrate markedly enhances intestinal aluminum absorption  (<a class="graphic graphic_figure graphicRef55777" href="/d/graphic/55777.html" rel="external">figure 1</a>) both by keeping aluminum soluble (via the formation of aluminum citrate) and by complexing with calcium in the intestinal lumen [<a href="#rid33">33,34</a>]. (See <a class="local">'Aluminum with citrate'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who have large body stores of aluminum and are treated with high doses of <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a> (ie, 20 to 40 mg/kg).</p><p></p><p class="headingAnchor" id="H533968457"><span class="h1">DIAGNOSIS AND EVALUATION</span><span class="headingEndMark"> — </span>The diagnostic approach to aluminum toxicity depends upon whether toxicity is chronic or acute.</p><p class="headingAnchor" id="H533968709"><span class="h2">Chronic toxicity</span><span class="headingEndMark"> — </span>The diagnosis of chronic aluminum toxicity should be suspected in patients on hemodialysis who have the constellation of signs and symptoms including bone and muscle pain, weakness, iron-resistant anemia, and neurologic changes, especially if in the setting of known aluminum exposure (such as aluminum-containing phosphate binders).</p><p>While a definitive diagnosis is made by the demonstration of aluminum deposition on bone biopsy, in practice, bone biopsies are rarely done since the expertise to perform and interpret the biopsy is frequently not available. Bone biopsy shows increased aluminum staining of the bone surface (&gt;15 to 25 percent) and often adynamic bone or osteomalacia [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/d/html/7239.html" rel="external">"Evaluation of renal osteodystrophy"</a>.)</p><p>In the absence of a bone biopsy, the diagnosis is based upon the baseline (ie, unstimulated) serum aluminum concentration, followed by, in selected patients, the deferoxamine-stimulated serum aluminum level. </p><p>The <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a> stimulation test measures the rise in serum aluminum concentration after an intravenous infusion of deferoxamine. The test is considered positive if there is an increase in serum aluminum of ≥50 mcg/L after administration of deferoxamine. Among patients with mildly elevated (ie, 20 to 60 mcg/L) serum aluminum concentrations, the deferoxamine stimulation test provides a more accurate measure of tissue aluminum concentration than is provided by the unstimulated serum concentration, which may just reflect a recent, limited exposure to aluminum [<a href="#rid60">60-63</a>]. In addition to providing a more accurate diagnosis among patients with mildly elevated unstimulated serum aluminum concentrations, the deferoxamine stimulation test is also used to guide treatment in patients. (See <a class="local">'Treatment'</a> below.)</p><p>The optimal <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a> dose and regimen for testing are not clear. We suggest that, for patients who require testing, deferoxamine at a dose of 5 mg/kg be administered one hour prior to the end of the dialysis session. There does not appear to be any benefit to using higher doses of deferoxamine. Two studies have shown comparable diagnostic sensitivity when 5 and 10 mg/kg test doses are used [<a href="#rid44">44,64</a>]. High doses of deferoxamine (40 mg/kg) have been associated with toxic side effects including irreversible ophthalmologic damage and mucormycosis [<a href="#rid65">65</a>]. (See <a class="local">'Adverse effects of deferoxamine'</a> below.)</p><p>The serum aluminum should be measured prior to and two days after the <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a> infusion (before the next dialysis session). The test is considered positive if there is an increase in serum aluminum of ≥50 mcg/L.</p><p>We select patients for deferoxamine-stimulated serum aluminum levels based upon the serum aluminum level and the presence or absence of typical symptoms  (<a class="graphic graphic_algorithm graphicRef96380" href="/d/graphic/96380.html" rel="external">algorithm 1</a>) [<a href="#rid20">20</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unstimulated serum aluminum levels &lt;20 mcg/L</strong> – Aluminum toxicity is unlikely in patients with baseline unstimulated serum aluminum concentrations &lt;20 mcg/L [<a href="#rid20">20</a>]. Such patients do not require further testing with the <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a> stimulation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asymptomatic, unstimulated aluminum levels 20 to 60 mcg/L</strong> – Among patients who have no symptoms of toxicity and are found to have unstimulated serum aluminum concentration of 20 to 60 mcg/L on routine screening, we suggest not performing a <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a> stimulation test. Among such patients, the risk of deferoxamine toxicity (either for diagnostic testing or treatment) outweighs any known benefit. Such patients should have a comprehensive review of medications to exclude aluminum-containing medications. Serum aluminum concentrations should be repeated in one month. (See  <a class="medical medical_review" href="/d/html/1896.html" rel="external">"Assuring water quality for hemodialysis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptomatic, unstimulated serum aluminum levels 20 to 60 mcg/L</strong> – Among patients who have an unstimulated serum aluminum concentration between 20 and 60 mcg/L who have symptoms of aluminum toxicity, we suggest <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a> stimulation testing to confirm diagnosis and to guide treatment if the deferoxamine stimulation test is positive. Patients who have a negative deferoxamine stimulation test should have the unstimulated aluminum concentration rechecked after one month since the initial level may have reflected a recent, limited exposure to aluminum. (See <a class="local">'Symptomatic patients'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unstimulated serum aluminum levels 60 to 200 mcg/L</strong> – Among all patients who have unstimulated serum aluminum concentration between 60 and 200 mcg/L, we suggest <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a> stimulation testing, whether or not symptoms of toxicity are present. Unstimulated serum aluminum concentrations &gt;60 strongly support the diagnosis of aluminum toxicity. In such patients, the deferoxamine stimulation test is used to guide the treatment approach. (See <a class="local">'Treatment'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unstimulated serum aluminum levels &gt;200 mcg/L</strong> – Patients with serum aluminum levels &gt;200 mcg/L are very likely to have aluminum toxicity. However, the <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a> test should <strong>not</strong> be performed in such patients. This is because the administration of deferoxamine causes severe, and occasionally fatal, neurotoxicity when it is administered to patients with very high serum aluminum concentrations [<a href="#rid66">66,67</a>]. This is presumed to be related to deferoxamine-induced mobilization of aluminum that has been deposited in tissues, resulting in transiently increased aluminum concentrations in the cerebrospinal fluid [<a href="#rid68">68</a>]. (See <a class="local">'Adverse effects of deferoxamine'</a> below.)</p><p></p><p class="headingAnchor" id="H533966933"><span class="h2">Acute toxicity</span><span class="headingEndMark"> — </span>Acute aluminum neurotoxicity is diagnosed when consistent clinical features (ie, encephalopathy) are associated with increased serum aluminum levels of 400 to 1000 mcg/L [<a href="#rid20">20</a>]. <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">Deferoxamine</a> testing is not done among such patients.</p><p class="headingAnchor" id="H13"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H533968916"><span class="h2">Our approach</span><span class="headingEndMark"> — </span>Treatment for aluminum toxicity includes all or some of the following interventions:</p><p class="bulletIndent1"><span class="glyph">●</span>Identification and removal of all sources of aluminum</p><p class="bulletIndent1"><span class="glyph">●</span>Intensive (six days per week) dialysis with high-flux dialysis</p><p class="bulletIndent1"><span class="glyph">●</span>Administration of <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a></p><p></p><p>The optimal approach is not known. Our approach is generally consistent with the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines [<a href="#rid20">20</a>] and is based on the severity of stimulated or unstimulated aluminum concentrations along with the presence or absence of characteristic symptoms.</p><p>All patients with increased unstimulated serum aluminum (ie, &gt;20 mcg/L) should be assessed for sources of aluminum exposure. Drugs, including over-the-counter preparations, should be reviewed for potential aluminum content. Agents that are obvious sources of aluminum (such as aluminum-containing phosphate binders) should be discontinued, if at all possible. All medications that are not absolutely necessary and that may contain small amounts of aluminum should be discontinued. (See <a class="local">'Other medications'</a> above.)</p><p>Our approach for symptomatic patients and for patients with increased aluminum concentrations detected by routine screening is described below  (<a class="graphic graphic_algorithm graphicRef96111" href="/d/graphic/96111.html" rel="external">algorithm 2</a> and <a class="graphic graphic_algorithm graphicRef96112" href="/d/graphic/96112.html" rel="external">algorithm 3</a>).</p><p class="headingAnchor" id="H533968922"><span class="h2">Symptomatic patients</span></p><p class="headingAnchor" id="H533975281"><span class="h3">Serum concentration 20 to 200 mcg/L</span><span class="headingEndMark"> — </span>All symptomatic patients with unstimulated serum aluminum 20 to 200 mcg/L should undergo <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a> stimulation testing to determine the optimal treatment. Our approach is as follows  (<a class="graphic graphic_algorithm graphicRef96111" href="/d/graphic/96111.html" rel="external">algorithm 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Deferoxamine-stimulated aluminum concentration increase of 50 to 299 mcg/L</strong> – We give <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a> 5 mg/kg weekly for eight doses. Deferoxamine removes aluminum that has been deposited in tissue [<a href="#rid69">69-73</a>]. There are no good randomized trials that have examined the efficacy of deferoxamine for aluminum toxicity. However, in small clinical series and in case reports, deferoxamine has been shown to decrease the symptoms of bone pain [<a href="#rid60">60,71,74</a>], proximal muscle weakness [<a href="#rid60">60,71,74</a>], neurologic symptoms [<a href="#rid75">75-79</a>], and anemia [<a href="#rid56">56,80,81</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">Deferoxamine</a> is generally given intravenously over the last hour of hemodialysis. However, if there are side effects to deferoxamine administration (such as nausea, pruritus, myalgias, hypotension, anaphylaxis, or neurologic changes), deferoxamine should be given five hours prior to the performance of high-efficiency hemodialysis (see  <a class="medical medical_review" href="/d/html/1844.html" rel="external">"Dialysis modality and patient outcome", section on 'High-flux and high-efficiency hemodialysis'</a>). This strategy should maximize removal of the deferoxamine-aluminum complex, which is presumed to cause the toxic effects [<a href="#rid82">82</a>].</p><p></p><p class="bulletIndent1">We repeat the <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a> stimulation test one month after completion of the eight-week course. If there is an increase in deferoxamine-stimulated aluminum concentration of 50 to 299 mcg/L, we give eight more weekly doses of 5 mg/kg and repeat the stimulation test after an additional month.</p><p></p><p class="bulletIndent1">If, after eight weeks of treatment, the deferoxamine-stimulated aluminum increases by &lt;50 mcg/L, then no further <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a> is given. The stimulation test should be repeated at one month and again at four months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Deferoxamine-stimulated aluminum concentration increase of ≥300 mcg/L</strong> – We give <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a> 5 mg/kg weekly for 16 doses (four months). Deferoxamine is given over one hour, five hours prior to the performance of high-efficiency hemodialysis (see  <a class="medical medical_review" href="/d/html/1844.html" rel="external">"Dialysis modality and patient outcome", section on 'High-flux and high-efficiency hemodialysis'</a>). This strategy should maximize removal of the deferoxamine-aluminum complex and minimize side effects [<a href="#rid82">82</a>].</p><p></p><p class="bulletIndent1">We repeat the <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a> stimulation test one month after the 16-week course. If there is an increase in deferoxamine-stimulated aluminum concentration &gt;300 mcg/L, we give an additional 16 weekly doses of deferoxamine 5 mg/kg.</p><p></p><p class="bulletIndent1">If there is an increase 50 to 299 mcg/L, we give an additional eight weekly doses of <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a> 5 mg/kg. The stimulation test is repeated one month after completion of the eight-week course.</p><p></p><p class="headingAnchor" id="H533975311"><span class="h3">Serum concentration &gt;200 mcg/L</span><span class="headingEndMark"> — </span>Patients with unstimulated serum aluminum &gt;200 mcg/L should not undergo a <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a> stimulation test (see <a class="local">'Chronic toxicity'</a> above). We also do not treat such patients with deferoxamine. The administration of deferoxamine causes severe and occasionally fatal neurotoxicity when it is administered to patients with very high serum aluminum concentrations [<a href="#rid66">66,67</a>]. This is thought to be related to deferoxamine-induced mobilization of aluminum that has been deposited in tissues, which causes transient increases in aluminum concentrations in the cerebrospinal fluid [<a href="#rid68">68</a>].</p><p>Such patients should be treated with intensive hemodialysis (six times per week) for four to six weeks or as long as is required for the serum aluminum concentration to decrease to &lt;200 mcg/L. A high-flux dialysis membrane should be used to provide the maximum clearance of aluminum [<a href="#rid82">82</a>] (see  <a class="medical medical_review" href="/d/html/1844.html" rel="external">"Dialysis modality and patient outcome", section on 'High-flux and high-efficiency hemodialysis'</a>). The dialysis fluid aluminum concentration should be ≤5 mcg/L, which is approximately half the maximum concentration for aluminum allowed by international standards  (<a class="graphic graphic_table graphicRef71221" href="/d/graphic/71221.html" rel="external">table 1</a>) [<a href="#rid83">83</a>]. (See  <a class="medical medical_review" href="/d/html/1891.html" rel="external">"Contaminants in water used for hemodialysis", section on 'Aluminum'</a>.)</p><p>These measures are continued for at least four to six weeks and until serum aluminum levels are &lt;200 mcg/L. If the baseline serum aluminum is reduced to &lt;200 mcg/L after intensive hemodialysis, a low-dose <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a> test is performed, with subsequent treatment based upon the results of the stimulation test. (See <a class="local">'Serum concentration 20 to 200 mcg/L'</a> above.)</p><p class="headingAnchor" id="H533969584"><span class="h2">Asymptomatic patients (increased aluminum detected on routine screening)</span></p><p class="headingAnchor" id="H1121249300"><span class="h3">Serum concentration 20 to 60 mcg/L</span><span class="headingEndMark"> — </span>As noted above, we do not perform <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a> stimulation testing on patients who have aluminum concentrations 20 to 60 mcg/L and have no symptoms of toxicity. We also do not treat such patients with deferoxamine, since the risk of deferoxamine toxicity outweighs any known benefit. Such patients are assessed for sources of aluminum exposure, including prescription and nonprescription medications. All medications that are not absolutely necessary and which may contain small amounts of aluminum should be discontinued  (<a class="graphic graphic_algorithm graphicRef96112" href="/d/graphic/96112.html" rel="external">algorithm 3</a>).</p><p class="headingAnchor" id="H1121249317"><span class="h3">Serum concentration &gt;60 mcg/L</span><span class="headingEndMark"> — </span>Patients who have serum aluminum concentrations of &gt;60 mcg/L should be treated the same as patients with similar aluminum concentrations who have symptoms of toxicity  (<a class="graphic graphic_algorithm graphicRef96112" href="/d/graphic/96112.html" rel="external">algorithm 3</a>). (See <a class="local">'Symptomatic patients'</a> above.)</p><p class="headingAnchor" id="H15"><span class="h1">ADVERSE EFFECTS OF DEFEROXAMINE</span><span class="headingEndMark"> — </span>Major side effects with <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a> therapy include neurotoxicity [<a href="#rid66">66,67</a>] and increased risk of mucormycosis [<a href="#rid65">65</a>]. Neurotoxicity may result from transiently increased concentrations of aluminum in the cerebrospinal fluid [<a href="#rid68">68</a>]. The risk of mucormycosis increases because deferoxamine chelation of iron enhances the growth and pathogenicity of <em>Rhizopus</em> species [<a href="#rid84">84,85</a>]. (See  <a class="medical medical_review" href="/d/html/2465.html" rel="external">"Mucormycosis (zygomycosis)", section on 'Deferoxamine and iron overload'</a>.)</p><p><a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">Deferoxamine</a> can also cause nausea, pruritus, myalgias, hypotension, and anaphylaxis [<a href="#rid66">66,86</a>].</p><p>There is an increased risk of adverse effects among patients who have high serum aluminum concentrations or are treated with high doses of <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a>.</p><p class="headingAnchor" id="H1591656912"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110749.html" rel="external">"Society guideline links: Chronic kidney disease in adults"</a>.)</p><p class="headingAnchor" id="H195553226"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Aluminum toxicity is a complication observed in hemodialysis patients that results from exposure to aluminum in dialysis fluid and in aluminum-containing phosphate binders. Aluminum toxicity is uncommon in developed countries with improved purification techniques for dialysis fluid and with availability of nonaluminum-containing phosphate binders. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The major sources of aluminum exposure for hemodialysis patients include the dialysis fluid and aluminum-containing phosphate binders and antacids. The ingestion of both aluminum and citrate-containing medications (such as Bicitra or Shohl’s solution and possibly <a class="drug drug_general" data-topicid="96959" href="/d/drug information/96959.html" rel="external">ferric citrate</a>) increases the risk of aluminum toxicity for chronic kidney disease (CKD) patients since citrate enhances the absorption of aluminum. Other medications also contain small amounts of aluminum that may accumulate in end-stage kidney disease (ESKD) patients. (See <a class="local">'Sources of aluminum'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We selectively monitor at-risk patients with serum aluminum levels:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In locations where water purification systems may be inadequate or aluminum-based phosphate binders are still prescribed, we suggest measuring serum aluminum every four to six months. Patients who have serum aluminum concentration &gt;20 mcg/L should be evaluated further for aluminum toxicity. (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who are undergoing parathyroid surgery for CKD-related secondary hyperparathyroidism and who have a history of aluminum exposure should undergo screening with an unstimulated serum aluminum concentration. If the unstimulated concentration is &lt;200 mcg/L, such patients should have further testing with a <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a> stimulation test. (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Manifestations of chronic aluminum toxicity include bone and muscle pain, weakness, osteomalacia, iron-resistant microcytic anemia, hypercalcemia, and slowly progressive dementia. This can occur in the setting of aluminum levels that are 20 mcg/L or greater.</p><p></p><p class="bulletIndent1">The major clinical manifestation of acute aluminum toxicity is encephalopathy, which can be fatal. Increased serum levels of aluminum of 400 to 1000 mcg/L are typically observed. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of aluminum toxicity is based upon the baseline (ie, unstimulated) serum aluminum concentration and followed by, in selected patients, a deferoxamine-stimulated serum aluminum level  (<a class="graphic graphic_algorithm graphicRef96380" href="/d/graphic/96380.html" rel="external">algorithm 1</a>). To test with <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a>, we administer deferoxamine at a dose of 5 mg/kg one hour prior to the end of the dialysis session. The serum aluminum is measured prior to and two days after the deferoxamine infusion (before the next dialysis session). The test is considered positive if there is an increase in serum aluminum of ≥50 mcg/L.</p><p></p><p class="bulletIndent1">Patients with serum aluminum levels &gt;200 mcg/L should <strong>not</strong> undergo a <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a> stimulation test, because the administration of deferoxamine may cause severe, and occasionally fatal, neurotoxicity when it is administered to patients with very high unstimulated serum aluminum concentrations. (See <a class="local">'Chronic toxicity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Our approach to treatment is consistent with the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines and is summarized in the algorithms  (<a class="graphic graphic_algorithm graphicRef96111" href="/d/graphic/96111.html" rel="external">algorithm 2</a> and <a class="graphic graphic_algorithm graphicRef96112" href="/d/graphic/96112.html" rel="external">algorithm 3</a>).</p><p></p><p class="bulletIndent1">All patients with consistently increased serum aluminum (ie, &gt;20 mcg/L) should be assessed for sources of aluminum exposure. Aluminum-containing phosphate binders and all other medications that may contain even small amounts of aluminum should be discontinued, if possible. (See <a class="local">'Our approach'</a> above.)</p><p></p><p class="bulletIndent1">All symptomatic patients who have unstimulated serum aluminum 20 to 200 mcg/L should undergo <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a> stimulation testing to determine the optimal treatment.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with a deferoxamine-stimulated aluminum concentration increase of 50 to 299 mcg/L, we suggest <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Serum concentration 20 to 200 mcg/L'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with deferoxamine-stimulated aluminum concentration increase of ≥300 mcg/L, we suggest <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Serum concentration 20 to 200 mcg/L'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with unstimulated serum aluminum &gt;200 mcg/L, we suggest intensive hemodialysis (six times per week) for at least four weeks and as long as is required for the serum aluminum concentration to decrease to &lt;200 mcg/L. (See <a class="local">'Serum concentration &gt;200 mcg/L'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The treatment of asymptomatic patients who have increased serum aluminum detected on routine screening is based upon the unstimulated aluminum concentration and, in selected patients, the deferoxamine-stimulated concentration.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with unstimulated aluminum concentrations 20 to 60 mcg/L, we suggest <strong>NOT</strong> treating with <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_3" rel="external">Grade 1C</a>) (see <a class="local">'Serum concentration 20 to 60 mcg/L'</a> above). The risk of deferoxamine toxicity outweighs any known benefit. Such patients are assessed for sources of aluminum exposure, including prescription and nonprescription medications. All medications that are not absolutely necessary and that may contain small amounts of aluminum should be discontinued.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who have asymptomatic serum aluminum concentrations of &gt;60 mcg/L should be treated the same as patients with similar aluminum concentrations who have symptoms of toxicity. (See <a class="local">'Serum concentration &gt;60 mcg/L'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Major side effects with <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a> therapy include neurotoxicity and increased risk of mucormycosis. Deferoxamine can also cause nausea, pruritus, myalgias, hypotension, and anaphylaxis. There is an increased risk of adverse effects among patients who have high serum aluminum concentrations or are treated with high doses of deferoxamine. (See <a class="local">'Adverse effects of deferoxamine'</a> above.)</p><p></p><p class="headingAnchor" id="H692045165"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledge Robert E Cronin, MD, and William L Henrich, MD, MACP, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Pierides AM, Edwards WG Jr, Cullum UX Jr, et al. Hemodialysis encephalopathy with osteomalacic fractures and muscle weakness. Kidney Int 1980; 18:115.</a></li><li><a class="nounderline abstract_t">Jaffe JA, Liftman C, Glickman JD. Frequency of elevated serum aluminum levels in adult dialysis patients. Am J Kidney Dis 2005; 46:316.</a></li><li><a class="nounderline abstract_t">Sharma AK, Toussaint ND, Pickering J, et al. Assessing the utility of testing aluminum levels in dialysis patients. Hemodial Int 2015; 19:256.</a></li><li><a class="nounderline abstract_t">Schifman RB, Luevano DR. Aluminum Toxicity: Evaluation of 16-Year Trend Among 14 919 Patients and 45 480 Results. Arch Pathol Lab Med 2018; 142:742.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Elevated serum aluminum levels in hemodialysis patients associated with use of electric pumps--Wyoming, 2007. MMWR Morb Mortal Wkly Rep 2008; 57:689.</a></li><li><a class="nounderline abstract_t">Sandhu G, Djebali D, Bansal A, et al. Serum concentrations of aluminum in hemodialysis patients. Am J Kidney Dis 2011; 57:523.</a></li><li><a class="nounderline abstract_t">Malluche HH, Mawad HW, Monier-Faugere MC. Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res 2011; 26:1368.</a></li><li><a class="nounderline abstract_t">Araújo SM, Ambrosoni P, Lobão RR, et al. The renal osteodystrophy pattern in Brazil and Uruguay: an overview. Kidney Int Suppl 2003; :S54.</a></li><li><a class="nounderline abstract_t">Jorgetti V, López BD, Caorsi H, et al. Different patterns of renal osteodystrophy in Iberoamerica. Am J Med Sci 2000; 320:76.</a></li><li><a class="nounderline abstract_t">Carbonara CEM, Reis LMD, Quadros KRDS, et al. Renal osteodystrophy and clinical outcomes: data from the Brazilian Registry of Bone Biopsies - REBRABO. J Bras Nefrol 2020; 42:138.</a></li><li><a class="nounderline abstract_t">Caramelo CA, Cannata JB, Rodeles MR, et al. Mechanisms of aluminum-induced microcytosis: lessons from accidental aluminum intoxication. Kidney Int 1995; 47:164.</a></li><li><a class="nounderline abstract_t">Burwen DR, Olsen SM, Bland LA, et al. Epidemic aluminum intoxication in hemodialysis patients traced to use of an aluminum pump. Kidney Int 1995; 48:469.</a></li><li><a class="nounderline abstract_t">Alfrey AC. Aluminum toxicity in patients with chronic renal failure. Ther Drug Monit 1993; 15:593.</a></li><li><a class="nounderline abstract_t">Bakir AA, Hryhorczuk DO, Berman E, Dunea G. Acute fatal hyperaluminemic encephalopathy in undialyzed and recently dialyzed uremic patients. ASAIO Trans 1986; 32:171.</a></li><li><a class="nounderline abstract_t">Molitoris BA, Froment DH, Mackenzie TA, et al. Citrate: a major factor in the toxicity of orally administered aluminum compounds. Kidney Int 1989; 36:949.</a></li><li><a class="nounderline abstract_t">Delmez JA, Slatopolsky E. Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 1992; 19:303.</a></li><li><a class="nounderline abstract_t">Slatopolsky E. The interaction of parathyroid hormone and aluminum in renal osteodystrophy. Kidney Int 1987; 31:842.</a></li><li><a class="nounderline abstract_t">Cannata-Andía JB, Fernández-Martín JL. The clinical impact of aluminium overload in renal failure. Nephrol Dial Transplant 2002; 17 Suppl 2:9.</a></li><li><a class="nounderline abstract_t">Salusky IB, Foley J, Nelson P, Goodman WG. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. N Engl J Med 1991; 324:527.</a></li><li><a class="nounderline abstract_t">National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42:S1.</a></li><li><a class="nounderline abstract_t">Bichu S, Tilve P, Kakde P, et al. Relationship between the Use of Aluminium Utensils for Cooking Meals and Chronic Aluminum Toxicity in Patients on Maintenance Hemodialysis: A Case Control Study. J Assoc Physicians India 2019; 67:52.</a></li><li><a class="nounderline abstract_t">Lin JL, Yang YJ, Yang SS, Leu ML. Aluminum utensils contribute to aluminum accumulation in patients with renal disease. Am J Kidney Dis 1997; 30:653.</a></li><li><a class="nounderline abstract_t">Alfrey AC, Mishell JM, Burks J, et al. Syndrome of dyspraxia and multifocal seizures associated with chronic hemodialysis. Trans Am Soc Artif Intern Organs 1972; 18:257.</a></li><li><a class="nounderline abstract_t">Flendrig JA, Kruis H, Das HA. Letter: Aluminum and dialysis dementia. Lancet 1976; 1:1235.</a></li><li><a class="nounderline abstract_t">Dunea G, Mahurkar SD, Mamdani B, Smith EC. Role of aluminum in dialysis dementia. Ann Intern Med 1978; 88:502.</a></li><li><a class="nounderline abstract_t">Reina de la Torre ML, Lopez García de la Serrana H, Martí Del Moral L, et al. Increased Serum Al Levels in Hemodialysis Patients Kept Enhanced during a 2-Year Prospective Study. Biol Trace Elem Res 2016.</a></li><li><a class="nounderline abstract_t">Berend K, van der Voet G, Boer WH. Acute aluminum encephalopathy in a dialysis center caused by a cement mortar water distribution pipe. Kidney Int 2001; 59:746.</a></li><li><a class="nounderline abstract_t">Lavergne V, Ghannoum M, Christie M, et al. Risk factors and consequences of hyperaluminemia in a peritoneal dialysis cohort. Perit Dial Int 2012; 32:645.</a></li><li><a class="nounderline abstract_t">Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; :S1.</a></li><li><a class="nounderline abstract_t">Bikbov B, Bieber B, Andrusev A, et al. Hemodialysis practice patterns in the Russia Dialysis Outcomes and Practice Patterns Study (DOPPS), with international comparisons. Hemodial Int 2016.</a></li><li><a class="nounderline abstract_t">Edalat-Nejad M, Ghasemikhah R, Delavar M. Aluminum overload: still as a source of concern in hemodialysis patients. Saudi J Kidney Dis Transpl 2014; 25:412.</a></li><li><a class="nounderline abstract_t">Kan WC, Chien CC, Wu CC, et al. Comparison of low-dose deferoxamine versus standard-dose deferoxamine for treatment of aluminium overload among haemodialysis patients. Nephrol Dial Transplant 2010; 25:1604.</a></li><li><a class="nounderline abstract_t">Nolan CR, Califano JR, Butzin CA. Influence of calcium acetate or calcium citrate on intestinal aluminum absorption. Kidney Int 1990; 38:937.</a></li><li><a class="nounderline abstract_t">Walker JA, Sherman RA, Cody RP. The effect of oral bases on enteral aluminum absorption. Arch Intern Med 1990; 150:2037.</a></li><li><a class="nounderline abstract_t">Froment DP, Molitoris BA, Buddington B, et al. Site and mechanism of enhanced gastrointestinal absorption of aluminum by citrate. Kidney Int 1989; 36:978.</a></li><li><a class="nounderline abstract_t">Van Buren PN, Lewis JB, Dwyer JP, et al. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial. Am J Kidney Dis 2015; 66:479.</a></li><li><a class="nounderline abstract_t">Gupta A. Ferric citrate hydrate as a phosphate binder and risk of aluminum toxicity. Pharmaceuticals (Basel) 2014; 7:990.</a></li><li><a class="nounderline abstract_t">Bohrer D, Bertagnolli DC, de Oliveira SM, et al. Drugs as a hidden source of aluminium for chronic renal patients. Nephrol Dial Transplant 2007; 22:605.</a></li><li><a class="nounderline abstract_t">Gura KM. Aluminum contamination in products used in parenteral nutrition: has anything changed? Nutrition 2010; 26:585.</a></li><li><a class="nounderline abstract_t">Reinke CM, Breitkreutz J, Leuenberger H. Aluminium in over-the-counter drugs: risks outweigh benefits? Drug Saf 2003; 26:1011.</a></li><li><a class="nounderline abstract_t">Hemstreet BA. Use of sucralfate in renal failure. Ann Pharmacother 2001; 35:360.</a></li><li><a class="nounderline abstract_t">Bohrer D, Bertagnolli DC, de Oliveira SM, et al. Role of medication in the level of aluminium in the blood of chronic haemodialysis patients. Nephrol Dial Transplant 2009; 24:1277.</a></li><li><a class="nounderline abstract_t">Gault PM, Allen KR, Newton KE. Plasma aluminium: a redundant test for patients on dialysis? Ann Clin Biochem 2005; 42:51.</a></li><li><a class="nounderline abstract_t">D'Haese PC, Couttenye MM, Goodman WG, et al. Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload. Nephrol Dial Transplant 1995; 10:1874.</a></li><li><a class="nounderline abstract_t">Barreto FC, Araújo SM, Sociedade Brasileira de Nefrologia. [Aluminium intoxication in chronic kidney disease]. J Bras Nefrol 2011; 33 Suppl 1:21.</a></li><li><a class="nounderline abstract_t">Oliveira RB, Barreto FC, Nunes LA, Custódio MR. Aluminum Intoxication in Chronic Kidney Disease. J Bras Nefrol 2021; 43:660.</a></li><li><a class="nounderline abstract_t">Netter P, Kessler M, Burnel D, et al. Aluminum in the joint tissues of chronic renal failure patients treated with regular hemodialysis and aluminum compounds. J Rheumatol 1984; 11:66.</a></li><li><a class="nounderline abstract_t">Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med 1995; 333:166.</a></li><li><a class="nounderline abstract_t">Andress DL, Norris KC, Coburn JW, et al. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 1989; 321:274.</a></li><li><a class="nounderline abstract_t">Recker R, Schoenfeld P, Letteri J, et al. The efficacy of calcifediol in renal osteodystrophy. Arch Intern Med 1978; 138 Spec No:857.</a></li><li><a class="nounderline abstract_t">Andress DL, Kopp JB, Maloney NA, et al. Early deposition of aluminum in bone in diabetic patients on hemodialysis. N Engl J Med 1987; 316:292.</a></li><li><a class="nounderline abstract_t">Pei Y, Hercz G, Greenwood C, et al. Renal osteodystrophy in diabetic patients. Kidney Int 1993; 44:159.</a></li><li><a class="nounderline abstract_t">Vincenti F, Arnaud SB, Recker R, et al. Parathyroid and bone response of the diabetic patient to uremia. Kidney Int 1984; 25:677.</a></li><li><a class="nounderline abstract_t">Santiago JV, McAlister WH, Ratzan SK, et al. Decreased cortical thickness &amp; osteopenia in children with diabetes mellitus. J Clin Endocrinol Metab 1977; 45:845.</a></li><li><a class="nounderline abstract_t">Vincenti F, Hattner R, Amend WJ Jr, et al. Decreased secondary hyperparathyroidism in diabetic patients receiving hemodialysis. JAMA 1981; 245:930.</a></li><li><a class="nounderline abstract_t">Touam M, Martinez F, Lacour B, et al. Aluminium-induced, reversible microcytic anemia in chronic renal failure: clinical and experimental studies. Clin Nephrol 1983; 19:295.</a></li><li class="breakAll">Oshiro S. A new effect of aluminum on iron metabolism in mammalian cells. In: Group 13 Chemistry II: Biological Aspects of Aluminum, Roesky HW, Atwood DA (Eds), Springer, New York 2002. Vol 104, p.59.</li><li><a class="nounderline abstract_t">Bansal VK, Bansal S. Nervous system disorders in dialysis patients. Handb Clin Neurol 2014; 119:395.</a></li><li><a class="nounderline abstract_t">Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med 1976; 294:184.</a></li><li><a class="nounderline abstract_t">McCarthy JT, Milliner DS, Johnson WJ. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity. Q J Med 1990; 74:257.</a></li><li><a class="nounderline abstract_t">Milliner DS, Nebeker HG, Ott SM, et al. Use of the deferoxamine infusion test in the diagnosis of aluminum-related osteodystrophy. Ann Intern Med 1984; 101:775.</a></li><li><a class="nounderline abstract_t">Kausz AT, Antonsen JE, Hercz G, et al. Screening plasma aluminum levels in relation to aluminum bone disease among asymptomatic dialysis patients. Am J Kidney Dis 1999; 34:688.</a></li><li><a class="nounderline abstract_t">D'Haese PC, Clement JP, Elseviers MM, et al. Value of serum aluminium monitoring in dialysis patients: a multicentre study. Nephrol Dial Transplant 1990; 5:45.</a></li><li><a class="nounderline abstract_t">Janssen MJ, van Boven WP. Efficacy of low-dose desferrioxamine for the estimation of aluminium overload in haemodialysis patients. Pharm World Sci 1996; 18:187.</a></li><li><a class="nounderline abstract_t">Boelaert JR, Fenves AZ, Coburn JW. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis 1991; 18:660.</a></li><li><a class="nounderline abstract_t">Sherrard DJ, Walker JV, Boykin JL. Precipitation of dialysis dementia by deferoxamine treatment of aluminum-related bone disease. Am J Kidney Dis 1988; 12:126.</a></li><li><a class="nounderline abstract_t">McCauley J, Sorkin MI. Exacerbation of aluminium encephalopathy after treatment with desferrioxamine. Nephrol Dial Transplant 1989; 4:110.</a></li><li><a class="nounderline abstract_t">Ellenberg R, King AL, Sica DA, et al. Cerebrospinal fluid aluminum levels following deferoxamine. Am J Kidney Dis 1990; 16:157.</a></li><li><a class="nounderline abstract_t">Malluche HH, Smith AJ, Abreo K, Faugere MC. The use of deferoxamine in the management of aluminium accumulation in bone in patients with renal failure. N Engl J Med 1984; 311:140.</a></li><li><a class="nounderline abstract_t">Andress DL, Nebeker HG, Ott SM, et al. Bone histologic response to deferoxamine in aluminum-related bone disease. Kidney Int 1987; 31:1344.</a></li><li><a class="nounderline abstract_t">Ott SM, Andress DL, Nebeker HG, et al. Changes in bone histology after treatment with desferrioxamine. Kidney Int Suppl 1986; 18:S108.</a></li><li><a class="nounderline abstract_t">Faugere MC, Arnala IO, Ritz E, Malluche HH. Loss of bone resulting from accumulation of aluminum in bone of patients undergoing dialysis. J Lab Clin Med 1986; 107:481.</a></li><li><a class="nounderline abstract_t">Charhon SA, Chavassieux P, Boivin G, et al. Deferoxamine-induced bone changes in haemodialysis patients: a histomorphometric study. Clin Sci (Lond) 1987; 73:227.</a></li><li><a class="nounderline abstract_t">Felsenfeld AJ, Rodriguez M, Coleman M, et al. Desferrioxamine therapy in hemodialysis patients with aluminum-associated bone disease. Kidney Int 1989; 35:1371.</a></li><li><a class="nounderline abstract_t">Ackrill P, Ralston AJ, Day JP, Hodge KC. Successful removal of aluminium from patient with dialysis encephalopathy. Lancet 1980; 2:692.</a></li><li><a class="nounderline abstract_t">Hood SA, Clark WF, Hodsman AB, et al. Successful treatment of dialysis osteomalacia and dementia, using desferrioxamine infusions and oral 1-alpha hydroxycholecalciferol. Am J Nephrol 1984; 4:369.</a></li><li><a class="nounderline abstract_t">Milne FJ, Sharf B, Bell P, Meyers AM. The effect of low aluminum water and desferrioxamine on the outcome of dialysis encephalopathy. Clin Nephrol 1983; 20:202.</a></li><li><a class="nounderline abstract_t">Sprague SM, Corwin HL, Wilson RS, et al. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity. Arch Intern Med 1986; 146:2063.</a></li><li><a class="nounderline abstract_t">Ackrill P, Ralston AJ, Day JP. Role of desferrioxamine in the treatment of dialysis encephalopathy. Kidney Int Suppl 1986; 18:S104.</a></li><li><a class="nounderline abstract_t">Bia MJ, Cooper K, Schnall S, et al. Aluminum induced anemia: pathogenesis and treatment in patients on chronic hemodialysis. Kidney Int 1989; 36:852.</a></li><li><a class="nounderline abstract_t">von Bonsdorff M, Sipilä R, Pitkänen E. Correction of haemodialysis-associated anaemia by deferoxamine. Effects on serum aluminum and iron overload. Scand J Urol Nephrol Suppl 1990; 131:49.</a></li><li><a class="nounderline abstract_t">Molitoris BA, Alfrey AC, Alfrey PS, Miller NL. Rapid removal of DFO-chelated aluminum during hemodialysis using polysulfone dialyzers. Kidney Int 1988; 34:98.</a></li><li class="breakAll">Association for the Advancement of Medical Instrumentation. Dialysate for Hemodialysis, ANSI/AAMI RD52:2004, Association for the Advancement of Medical Instrumentation, Arlington, VA 2004.</li><li><a class="nounderline abstract_t">Greenberg RN, Scott LJ, Vaughn HH, Ribes JA. Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Curr Opin Infect Dis 2004; 17:517.</a></li><li><a class="nounderline abstract_t">Boelaert JR, de Locht M, Van Cutsem J, et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest 1993; 91:1979.</a></li><li><a class="nounderline abstract_t">Knudsen PJ, Leon J, Ng AK, et al. Hemodialysis-related induction of beta-2-microglobulin and interleukin-1 synthesis and release by mononuclear phagocytes. Nephron 1989; 53:188.</a></li></ol></div><div id="topicVersionRevision">Topic 1839 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7218657" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hemodialysis encephalopathy with osteomalacic fractures and muscle weakness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16112051" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Frequency of elevated serum aluminum levels in adult dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25306885" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Assessing the utility of testing aluminum levels in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29509029" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Aluminum Toxicity: Evaluation of 16-Year Trend Among 14 919 Patients and 45 480 Results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18583956" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Elevated serum aluminum levels in hemodialysis patients associated with use of electric pumps--Wyoming, 2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21257246" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Serum concentrations of aluminum in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21611975" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12753266" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The renal osteodystrophy pattern in Brazil and Uruguay: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10981479" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Different patterns of renal osteodystrophy in Iberoamerica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32756862" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Renal osteodystrophy and clinical outcomes: data from the Brazilian Registry of Bone Biopsies - REBRABO.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7731142" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Mechanisms of aluminum-induced microcytosis: lessons from accidental aluminum intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7564114" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Epidemic aluminum intoxication in hemodialysis patients traced to use of an aluminum pump.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8122300" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Aluminum toxicity in patients with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3778707" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Acute fatal hyperaluminemic encephalopathy in undialyzed and recently dialyzed uremic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2689754" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Citrate: a major factor in the toxicity of orally administered aluminum compounds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1562018" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3573543" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The interaction of parathyroid hormone and aluminum in renal osteodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11904351" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The clinical impact of aluminium overload in renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1992306" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14520607" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31309799" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 :  Relationship between the Use of Aluminium Utensils for Cooking Meals and Chronic Aluminum Toxicity in Patients on Maintenance Hemodialysis: A Case Control Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9370180" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Aluminum utensils contribute to aluminum accumulation in patients with renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4215188" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Syndrome of dyspraxia and multifocal seizures associated with chronic hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/58273" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Letter: Aluminum and dialysis dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/637430" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Role of aluminum in dialysis dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27905009" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Increased Serum Al Levels in Hemodialysis Patients Kept Enhanced during a 2-Year Prospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11168958" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Acute aluminum encephalopathy in a dialysis center caused by a cement mortar water distribution pipe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22855887" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Risk factors and consequences of hyperaluminemia in a peritoneal dialysis cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19644521" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27790813" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Hemodialysis practice patterns in the Russia Dialysis Outcomes and Practice Patterns Study (DOPPS), with international comparisons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24626016" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Aluminum overload: still as a source of concern in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19948879" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Comparison of low-dose deferoxamine versus standard-dose deferoxamine for treatment of aluminium overload among haemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2266679" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Influence of calcium acetate or calcium citrate on intestinal aluminum absorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2171446" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The effect of oral bases on enteral aluminum absorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2601265" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Site and mechanism of enhanced gastrointestinal absorption of aluminum by citrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25958079" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25341358" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Ferric citrate hydrate as a phosphate binder and risk of aluminum toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17035374" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Drugs as a hidden source of aluminium for chronic renal patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20363591" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Aluminum contamination in products used in parenteral nutrition: has anything changed?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14583063" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Aluminium in over-the-counter drugs: risks outweigh benefits?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11261535" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Use of sucralfate in renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19028749" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Role of medication in the level of aluminium in the blood of chronic haemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15802033" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Plasma aluminium: a redundant test for patients on dialysis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8592597" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21655860" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : [Aluminium intoxication in chronic kidney disease].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34910802" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Aluminum Intoxication in Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6699835" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Aluminum in the joint tissues of chronic renal failure patients treated with regular hemodialysis and aluminum compounds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7791820" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Renal osteodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2631697" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/646574" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The efficacy of calcifediol in renal osteodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3807961" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Early deposition of aluminum in bone in diabetic patients on hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8355457" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Renal osteodystrophy in diabetic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6482171" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Parathyroid and bone response of the diabetic patient to uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/914988" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Decreased cortical thickness&amp;osteopenia in children with diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7007680" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Decreased secondary hyperparathyroidism in diabetic patients receiving hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6872366" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Aluminium-induced, reversible microcytic anemia in chronic renal failure: clinical and experimental studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6872366" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Aluminium-induced, reversible microcytic anemia in chronic renal failure: clinical and experimental studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24365308" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Nervous system disorders in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1244532" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The dialysis encephalopathy syndrome. Possible aluminum intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2117295" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6208838" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Use of the deferoxamine infusion test in the diagnosis of aluminum-related osteodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10516350" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Screening plasma aluminum levels in relation to aluminum bone disease among asymptomatic dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2109284" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Value of serum aluminium monitoring in dialysis patients: a multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8933580" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Efficacy of low-dose desferrioxamine for the estimation of aluminium overload in haemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1962650" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3400633" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Precipitation of dialysis dementia by deferoxamine treatment of aluminum-related bone disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2496351" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Exacerbation of aluminium encephalopathy after treatment with desferrioxamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2382654" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Cerebrospinal fluid aluminum levels following deferoxamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6377067" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The use of deferoxamine in the management of aluminium accumulation in bone in patients with renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2441107" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Bone histologic response to deferoxamine in aluminum-related bone disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3457986" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Changes in bone histology after treatment with desferrioxamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3486929" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Loss of bone resulting from accumulation of aluminum in bone of patients undergoing dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3652627" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Deferoxamine-induced bone changes in haemodialysis patients: a histomorphometric study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2770115" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Desferrioxamine therapy in hemodialysis patients with aluminum-associated bone disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6106803" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Successful removal of aluminium from patient with dialysis encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6517116" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Successful treatment of dialysis osteomalacia and dementia, using desferrioxamine infusions and oral 1-alpha hydroxycholecalciferol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6641027" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The effect of low aluminum water and desferrioxamine on the outcome of dialysis encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3767553" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3457985" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Role of desferrioxamine in the treatment of dialysis encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2615192" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Aluminum induced anemia: pathogenesis and treatment in patients on chronic hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2075470" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Correction of haemodialysis-associated anaemia by deferoxamine. Effects on serum aluminum and iron overload.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3172641" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Rapid removal of DFO-chelated aluminum during hemodialysis using polysulfone dialyzers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3172641" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Rapid removal of DFO-chelated aluminum during hemodialysis using polysulfone dialyzers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15640705" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Zygomycosis (mucormycosis): emerging clinical importance and new treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8486769" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2507949" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Hemodialysis-related induction of beta-2-microglobulin and interleukin-1 synthesis and release by mononuclear phagocytes.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
